机构：[1]The Centre for Reproductive and Genetic Health, 230-232 Great Portland St, Fitzrovia, London, W1W 5QS, UK.[2]Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Chicago Medical School, Rosalind Franklin University of Medicine and Science, Vernon Hills, IL, 60061, USA.[3]Department of Traditional Chinese Medicine Rheumatology, Shenzhen Nanshan People's Hospital, The 6th Affiliated Hospital, Shenzhen University Health Science Center, Shenzhen, Guangdong, China.深圳市康宁医院深圳市南山区人民医院深圳医学信息中心[4]Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Over the last few decades, the advancement in reproductive technologies and protocols to improve embryo quality through culture techniques and genetic testing to eliminate chromosomally abnormal embryos resulted in better pregnancy rates and outcomes after fertility treatments. Unfortunately, some patients still struggle with recurrent implantation failures (RIF) and recurrent pregnancy losses (RPL). Immune aetiologies have been attributed to play an important role in some of those patients. Maintaining a preconceptional anti-inflammatory environment for implantation and pregnancy continuation yields superior results. Intravenous immunoglobulin G (IVIG) treatment has been reported to enhance reproductive outcome in patients with RIF and RPL with immune dysregulations. In this systemic review, we analyzed outcomes of IVIG trials for RIF and RPL, its mechanism of action, dosing, administration, side effects, and evidence for its use in women with RIF and RPL.
This article is protected by copyright. All rights reserved.
第一作者机构：[1]The Centre for Reproductive and Genetic Health, 230-232 Great Portland St, Fitzrovia, London, W1W 5QS, UK.
通讯作者：
通讯机构：[2]Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department, Chicago Medical School, Rosalind Franklin University of Medicine and Science, Vernon Hills, IL, 60061, USA.[*1]Reproductive Medicine and Immunology, Obstetrics and Gynecology, Clinical Sciences Department,Chicago Medical School, Rosalind Franklin University of Medicine and Science, 830 West End Court, Suite 400, Vernon Hills, IL, 60061, USA
推荐引用方式(GB/T 7714)：
Saab Wael,Seshadri Srividya,Huang Changsheng,et al.A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses.[J].AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY.2021,85(4):doi:10.1111/aji.13395.
APA：
Saab Wael,Seshadri Srividya,Huang Changsheng,Alsubki Lujain,Sung Nayoung&Kwak-Kim Joanne.(2021).A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses..AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY,85,(4)
MLA：
Saab Wael,et al."A systemic review of intravenous immunoglobulin G treatment in women with recurrent implantation failures and recurrent pregnancy losses.".AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY 85..4(2021)
